US equities
|
NVDA
$135.83
▼-6.95%
ANT
$84.65
▼-12.88%
MU
$607.70
▼-11.98%
AMD
$434.38
▼-11.20%
AAPL
$346.05
▼-0.90%
SPCX
$128.95
▼-6.85%
MSFT
$488.90
▼-1.89%
AMZN
$250.55
▼-2.65%
NVDA
$135.83
▼-6.95%
ANT
$84.65
▼-12.88%
MU
$607.70
▼-11.98%
AMD
$434.38
▼-11.20%
AAPL
$346.05
▼-0.90%
SPCX
$128.95
▼-6.85%
MSFT
$488.90
▼-1.89%
AMZN
$250.55
▼-2.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Alnylam
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
May 20, 2023
From
Alnylam
Via
Business Wire
Tickers
ALNY